Company overview
Calla Lily Clinical Care develops Callavid®, a patented, leak-free, tampon-shaped intravaginal drug delivery device for consistent administration of therapeutics. Initial focus is on progesterone for miscarriage prevention and IVF support, with potential for oncology, menopause, bacterial vaginosis, and microbiome therapies. The FDA-cleared platform has secured NIHR funding, Innovate UK grants, and a 2026 strategic collaboration with Merck.
Innovators in Vaginal Drug Delivery is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include vaginal drug delivery, callavid platform, progesterone delivery, women's health medtech, intravaginal therapeutics.
Structured facts
- Website
- https://www.callali.ly
- Markets served
- United States & Americas
- Keywords
- vaginal drug delivery, callavid platform, progesterone delivery, women's health medtech, intravaginal therapeutics
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Callavid and its key capabilities?
- Callavid is a patented, tampon-shaped device providing leak-free, dosage-confident intravaginal drug delivery. It supports hygienic insertion, in-place absorption, and clean removal for therapeutics in fertility, pregnancy, oncology, menopause, and infections.
- What regulatory approvals and funding has the company received?
- Callavid's underlying technology has FDA clearance. The company has raised £2.3 million in funding, over £2 million in Innovate UK and NIHR grants, and announced a Merck collaboration in 2026.
- What geographies does Calla Lily Clinical Care serve?
- London-based, operating primarily in the United Kingdom with FDA clearance indicating US market potential. Clinical trials are progressing in the UK, targeting global women's health applications.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
